Adherence to multidosing is challenging worldwide. This study assessed the extent of adherence to multidosing artemether-lumefantrine (ALu) in a rural community in Tanzania, six years after switching from single dose policy of sulphadoxine-pyrimethamine. This study was a prospective observational, open label, non-randomized study involving 151 patients with uncomplicated malaria recruited at Fukayosi dispensary in Bagamoyo district in Tanzania. Patients treated with ALu were visited at home on day 3 for interview on drug intake, capillary blood sample collection for microscopy and ALu tablets count. Venous blood samples (2 ml) for determination of blood lumefantrine concentrations and blood slides for microscopy were collected on day-7. Kap...
Based on the recommendations of the World Health Organization in 2004, Ghana changed her antimalaria...
Prompt access to artemesinin-combination therapy (ACT) is not adequate unless the drug is taken acco...
Abstract. Artemisinin-containing antimalarial combination therapies are recommended to confront drug...
Background: Since November 2006, Coartem® (Artemether-Lumefantrine-ALu) replaced Sulphadoxine-Pyrime...
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important ...
A follow-up study was conducted to determine the magnitude of and factors related to adherence to ar...
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important ...
Abstract. Measuring baseline levels of adherence and identifying risk factors for non-adherence are ...
Abstract Background Sulphadoxine-pyrimethamine (SP) is the only single dose therapy for uncomplicate...
Adherence to artemisinin-based combination therapies (ACTs) for malaria is important for effective ...
Abstract Background Controlled clinical trials have shown that a six-dose regimen of artemether-lume...
BACKGROUND: Current day malaria cases and deaths are indicative of a lack of access to both methods ...
BackgroundArtemisinin combination therapy (ACT) is first-line treatment for malaria in most endemic ...
Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malaria in 2006. ...
As artemether/lumefantrine is now deployed as the first-line treatment for uncomplicated falciparum ...
Based on the recommendations of the World Health Organization in 2004, Ghana changed her antimalaria...
Prompt access to artemesinin-combination therapy (ACT) is not adequate unless the drug is taken acco...
Abstract. Artemisinin-containing antimalarial combination therapies are recommended to confront drug...
Background: Since November 2006, Coartem® (Artemether-Lumefantrine-ALu) replaced Sulphadoxine-Pyrime...
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important ...
A follow-up study was conducted to determine the magnitude of and factors related to adherence to ar...
Measuring baseline levels of adherence and identifying risk factors for non-adherence are important ...
Abstract. Measuring baseline levels of adherence and identifying risk factors for non-adherence are ...
Abstract Background Sulphadoxine-pyrimethamine (SP) is the only single dose therapy for uncomplicate...
Adherence to artemisinin-based combination therapies (ACTs) for malaria is important for effective ...
Abstract Background Controlled clinical trials have shown that a six-dose regimen of artemether-lume...
BACKGROUND: Current day malaria cases and deaths are indicative of a lack of access to both methods ...
BackgroundArtemisinin combination therapy (ACT) is first-line treatment for malaria in most endemic ...
Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malaria in 2006. ...
As artemether/lumefantrine is now deployed as the first-line treatment for uncomplicated falciparum ...
Based on the recommendations of the World Health Organization in 2004, Ghana changed her antimalaria...
Prompt access to artemesinin-combination therapy (ACT) is not adequate unless the drug is taken acco...
Abstract. Artemisinin-containing antimalarial combination therapies are recommended to confront drug...